Cholesterol guidelines setback

Share this article:

Last week's news that new cholesterol guidelines were in place revved up industry chatter about what this could mean for the statin market. Yet a problem has surfaced: the calculator that would help doctors calculate patient risk is not working right.

The New York Times reports that the calculator “could mistakenly suggest that millions more people are candidates for statin drugs.” The NYT says the American Heart Association and American College of Cardiology are saying that although the calculator is not running as expected, the tool is a sign of progress.

The two groups developed the new guidelines which focus less on cholesterol levels and more on heart disease/stroke risk if a patient has already made lifestyle changes (read: diet and exercise). The risks, as noted by CNN, include factors such as whether a patient is diabetic, and/or has heart disease. The NYT notes that target levels will still be important for patients with high LDL levels.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.